GSK plc ADR (GSK)
NYSE: GSKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GSK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $95.73B
- P/E (TTM)
- 16.64
- Forward P/E
- 9.63
- EPS (TTM)
- $2.87
- Dividend yield
- 1.44% ($0.69)
- Ex-dividend date
- Nov 13, 2026
- 52-week range
- 45.83 – 61.70
- Day range
- 47.70 – 48.72
- Volume / Avg
- 2.74M / 4.03M
- Beta
- —
- Shares outstanding
- 2.00B
52-week range
GSK stock today
Shares of GSK (GSK) finished lower on Nov 20 at $47.76, a drop of 0.13% or $0.06 per share, versus the S&P 500's 3.70% decline. Shares are 22.6% below their 52-week high of $61.70, set on Feb 18, 2026 and 4.2% above the 52-week low of $45.83, near the bottom of the past year's range. GSK is down 2.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 1.2%.
At 16.6x trailing earnings, GSK trades below the peer-group median of 33.1x. Its forward P/E of 9.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. GSK pays an annual dividend of $0.69 per share, a 1.44% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About GSK
Company profileGSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Luke Victor Miels
- Headquarters
- London
- Employees
- 66,841
- IPO year
- 2022
- Website
- gsk.com
Analyst forecast
ForecastConsensus (9 analysts)
hold
Avg. price target
$59.12+23.79%
- Strong buy 1
- Buy 2
- Hold 5
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 28, 2026
- EPS actual vs est.
- $1.48 vs $1.40
- Surprise
- +5.71%
Dividends
Dividend history- Annual dividend
- $0.69
- Dividend yield
- 1.44%
- Last payment
- $0.452
- Ex-dividend date
- Nov 13, 2026
GSK news
All GSK news- Top Analyst Reports for Berkshire Hathaway, JPMorgan & Procter & GambleNasdaqJPM, PG, BRK.B, NPK
- GSK's Velzatinib Gets Orphan Drug Designation In Japan For Gastrointestinal Stromal CancerNasdaq
- GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung CancerNasdaqGSK, ADPT, ACIU, AMRX
- GSK Wins FDA Approval For Nelkarmi In Previously Treated ALK-Positive Lung CancerNasdaq
- GSK CFO Points to Cancer Drugs to Bridge £3.4 Billion Sales Forecast GapNasdaq
- GSK Targets £40 Billion in Sales as HIV Patent Cliff LoomsNasdaq
- GSK: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?NasdaqGILD, GSK, MRK
GSK peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| REGNRegeneron Pharmaceuticals Inc. | 920.69 | -0.19% | $95.24B | vs GSK |
| SNYSanofi ADS | 46.52 | +1.00% | $111.70B | vs GSK |
| BMYBristol-Myers Squibb Company | 58.80 | +0.79% | $120.19B | vs GSK |
| TAKTakeda Pharmaceutical Company Limited ADR | 21.77 | +1.68% | $69.55B | vs GSK |
| VRTXVertex Pharmaceuticals Incorporated | 515.02 | -1.08% | $130.58B | vs GSK |
| TEVATeva Pharmaceutical Industries Limited | 39.23 | +1.79% | $45.77B | vs GSK |
| ONCBeOne Medicines Ltd. ADR | 390.94 | -2.19% | $44.66B | vs GSK |
| RPRXRoyalty Pharma plc Class A | 68.45 | +1.08% | $39.36B | vs GSK |
Indexes, lists and sector
GSK stock FAQ
What is GSK's stock price today?
GSK last traded at $47.76 as of Nov 20, 4:00 PM EST, down 0.13% on the day. Prices are delayed at least 15 minutes.
Does GSK pay a dividend?
Yes. GSK pays $0.69 per share annually, a 1.44% yield. The most recent dividend of $0.452 had an ex-dividend date of Nov 13, 2026.
What is GSK's P/E ratio?
GSK trades at a trailing P/E ratio of 16.64 and a forward P/E of 9.63, compared with a median of 33.1 for its closest peers.
Who is GSK's CEO?
Mr. Luke Victor Miels is the chief executive officer of GSK plc ADR, which has about 66,841 employees.
Has GSK ever split its stock?
Yes. The most recent GSK stock split was a 1226-for-1000 split on Jul 22, 2022, one of 5 splits on record.
What is the GSK 52-week high?
The 52-week high for GSK is $61.70 and the 52-week low is $45.83. The stock is currently 22.6% below its high.